Companies /Healthcare

Abbvie Inc

NYSE: ABBV Drug Manufacturers - General
$256.46
▼ $3.75 (−1.44%) today
Markets closed · 8:47pm ET

Q1 2025 Earnings

Reported Apr 25, 2025, 7:48am ET · SEC source
$2.46
Beat +2.62%
EPS · est. $2.40
$13.3B
Beat +3.27%
Revenue · est. $12.9B
−8.3%
Trailing market
ABBV vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−2%0+2%Apr 25Apr 25report 7:48am ETearnings+1.0%+0.6%
−2%0+2%Apr 25Apr 25earnings+1.0%+0.6%
ABBV +0.6%S&P 500 +1.0%
−2%0+2%Apr 25Apr 25report 7:48am ETearnings+1.4%+0.6%
−2%0+2%Apr 25Apr 25earnings+1.4%+0.6%
ABBV +0.6%NASDAQ +1.4%
−4%0+4%Apr 24May 2report 7:48am ETearnings+3.9%+6.3%
−4%0+4%Apr 24May 2earnings+3.9%+6.3%
ABBV +6.3%S&P 500 +3.9%
−4%0+4%Apr 24May 2report 7:48am ETearnings+4.9%+6.3%
−4%0+4%Apr 24May 2earnings+4.9%+6.3%
ABBV +6.3%NASDAQ +4.9%
+3.15%
Day of report
+3.38%
Next session
+6.67%
One week
−1.60%
30 days

S&P 500 over the same 30 days: +6.74%.

Did ABBV Beat Earnings? Q1 2025 Results

AbbVie opened 2025 on solid footing, posting first-quarter revenue of $13.34 billion, up 8.4% year over year and ahead of the $12.92 billion consensus estimate by 3.27%, while adjusted diluted EPS of $2.46 beat the $2.40 Wall Street forecast by 2.62%. The immunology franchise was the clear engine of growth, generating $6.26 billion in revenue as Skyrizi surged 70.5% to $3.42 billion and Rinvoq climbed 57.2% to $1.72 billion, more than compensating for Humira's continued biosimilar-driven erosion. Neuroscience also contributed meaningfully, rising 16.1% to $2.28 billion, though aesthetics remained a soft spot, declining 11.7% to $1.10 billion on weaker consumer demand for Botox Cosmetic and Juvederm. AbbVie used the strong quarter to lift its full-year 2025 adjusted diluted EPS guidance to a range of $12.09 to $12.29, though management noted the outlook excludes any impact from potential pharmaceutical tariffs, a topic on which the company has publicly advocated for tax reform over trade measures as the more effective lever for expanding U.S. manufacturing.

Key Takeaways
  • Skyrizi revenue growth of 70.5% driven by strong demand across indications
  • Rinvoq revenue growth of 57.2% with expanding indications including GCA approval in EU
  • Neuroscience portfolio growth of 16.1% led by Botox Therapeutic and migraine franchise
  • U.S. net revenues grew 10.4% year-over-year
  • Creon revenue grew 24.6% year-over-year

“AbbVie's first-quarter results were well ahead of our expectations and reflect an excellent start to the year.”

AbbVie CEO, on the earnings call

Forward Guidance & Outlook

AbbVie raised its full-year 2025 adjusted diluted EPS guidance to $12.09–$12.29 from the prior range of $11.99–$12.19. This includes an unfavorable $0.13 per share impact from acquired IPR&D and milestones expense incurred year-to-date through Q1 2025 but excludes any IPR&D and milestones impact beyond Q1 as those cannot be reliably forecasted. The guidance also excludes the IPR&D impact from the Gubra licensing agreement (which closed after Q1) and does not reflect any potential trade policy shifts, including pharmaceutical sector tariffs.

ABBV YoY Financials

Q1 2025 vs Q1 2024 · SEC filings Q1 2024 Q1 2025
$0$4.0B$8.0B$12.0B$12.3B$13.3BRevenue$8.2B$9.3BGross Profit$2.8B$3.7BOperating Income$1.4B$1.3BNet Income
$0$4.0B$8.0B$12.0BRevenueGross ProfitOperating IncomeNet Income

ABBV Revenue by Segment

Immunology$6.3B+16.6%
Skyrizi$3.4B+70.5%
Neuroscience$2.3B+16.1%
Rinvoq$1.7B+57.2%
Oncology$1.6B+5.8%
Aesthetics$1.1B−11.7%
Humira$1.1B−50.6%
Vraylar$765.0M+10.3%

ABBV Revenue by Geography

United States$10.0B+10.4%
Rest of World$3.4B+2.9%

Figures from SEC filings and company reports. Not investment advice.